Alpha-Galactosidase - Genzyme General: Fabrazyme®, Agalsidase Beta, Recombinant Human -Galactosidase A

Author：

ISSN： 1174-5886

Source： Drugs in R&D, Vol.4, Iss.2, 2003-01, pp. : 115-118

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beta‐galactosidase deficiency: Studies of two patients with prolonged survival

American Journal of Medical Genetics, Vol. 5, Iss. 3, 1980-01 ,pp. : 235-245

John Wiley & Sons Inc

Access to resources Recommend Favorite

Development and validation of fluorescent receptor assays based on the human recombinant estrogen receptor subtypes alpha and beta

By de Boer T. Otjens D. Muntendam A. Meulman E. van Oostijen M. Ensing K.

Journal of Pharmaceutical and Biomedical Analysis, Vol. 34, Iss. 3, 2004-02 ,pp. : 671-679

Elsevier

Access to resources Recommend Favorite

-Galactosidase replacement therapy in Fabry's disease

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Sevelamer [`Renagel'; Genzyme General] has received marketing approval in Brazil.

Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Agalsidase Beta: A Review of its Use in the Management of Fabry Disease

By Keating Gillian M. Simpson Dene

Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. : 435-455

Adis International

Access to resources Recommend Favorite